Refers to the Crystalline form of a compound of Hemi hydrate has the (S) - N - (S) - 1 - (Cyclohexyl - {2 - (S) - 2 - [4 - (4 - fluoro benzoyl) - thiazol-2-yl] - pyrrolidin-1-yl} - 2 - oxo - ethyl) - 2 - methyl - Amino propionamide of formula (i) comprising: (a) a pattern of Powder x-ray diffraction (XRPD) including t Values 2Theta res or more selected from the group consisting of: 8.3 + \/ - 0.2, 9.5\u00b10.2, 13.5\u00b10.2, 17.3\u00b10.2, 18.5\u00b10.2 and 18.9\u00b10.2 (b) a Crystalline form of the compound (i) showing a XRPD that includes three or more 2theta values selected from the group consisting of: 5.3\u00b10.2, 6.7\u00b10.2, 9.1\u00b10.2, 13.4\u00b10.2, 13.6\u00b10.2, 15.0\u00b10.2, 15.3\u00b10.2, 17.4\u00b10.2, 18.2\u00b10.2, 18.7 \u00b10.2, 18.9\u00b10.2, 20.2\u00b10.2, 21.3\u00b10.2, 21.8\u00b10.2, 23.0\u00b10.2, 23.5\u00b10.2, 24.6\u00b10.2 and 27.6\u00b10.2.In addition to such a Pharmaceutical composition. This Compound is an inhibitor of Apoptosis Proteins (IAPs) being useful for treating Diseases associated with the Protein of ApoptosisSE REFIERE A LA FORMA CRISTALINA DE UN COMPUESTO DE HEMI-HIDRATO HA DE LA (S) -N-((S)-1-CICLOHEXIL-2-{(S)-2-[4-(4-FLUORO-BENZOIL)-TIAZOL-2-IL]-PIRROLIDIN-1-IL}-2-OXO-ETIL)-2-METIL-AMINO-PROPIONAMIDA DE FORMULA (I) QUE COMPRENDE: (A) UN PATRON DE DIFRACCION EN POLVO DE RAYOS X (XRPD) QUE COMPRENDE TRES O MAS VALORES 2THETA SELECCIONADOS A PARTIR DEL GRUPO QUE CONSISTE EN: 8.3 ± 0.2, 9.5±0.2, 13.5±0.2, 17.3±0.2, 18.5±0.2 Y 18.9±0.2 (B) UNA FORMA CRISTALINA A DEL COMPUESTO (I) QUE PRESENTA UN XRPD QUE COMPRENDE TRES O MAS VALORES 2THETA SELECCIONADOS A PARTIR DEL GRUPO QUE CONSISTE EN: 5.3±0.2, 6.7±0.2, 9.1±0.2, 13.4±0.2, 13.6±0.2, 15.0±0.2, 15.3±0.2, 17.4±0.2, 18.2±0.2, 18.7±0.2, 18.9±0.2, 20.2±0.2, 21.3±0.2, 21.8±0.2, 23.0±0.2, 23.5±0.2, 24.6±0.2 Y 27.6±0.2. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE LA PROTEINA DE APOPTOSIS (IAPS) SIENDO UTIL PARA TRATAR ENFERMEDADES RELACIONAD
